Last reviewed · How we verify
adriacin
adriacin is a Small molecule drug developed by Chipscreen Biosciences, Ltd.. It is currently in Phase 1 development for Acute lymphoid leukemia, Acute myeloid leukemia, disease, Advanced ovarian cancer. Also known as: ADR.
Likelihood of approval
9.6%
vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | adriacin |
|---|---|
| Also known as | ADR |
| Sponsor | Chipscreen Biosciences, Ltd. |
| Target | Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Approved indications
- Acute lymphoid leukemia
- Acute myeloid leukemia, disease
- Advanced ovarian cancer
- Burkitt's lymphoma
- Carcinoma of breast
- Carcinoma of female breast
- Diffuse non-Hodgkin's lymphoma, large cell
- Follicular non-Hodgkin's lymphoma
- Hodgkin's disease
- Invasive Bladder Malignancy
- Kaposi's sarcoma
- Kaposi's sarcoma associated with AIDS
- Malignant tumor of lung
- Malignant tumor of ovary
- Malignant tumor of thyroid gland
- Metastatic Breast Carcinoma
- Metastatic Gastric Cancer
- Multiple myeloma
- Nephroblastoma
- Neuroblastoma
Common side effects
- Leukopenia Grade (1,000 to 1,999/mm3)
- Leukopenia Grade (<1,000/mm3)
- Thrombocytopenia Grade (25,000 to 49,999/mm3)
- Thrombocytopenia Grade (<25,000/mm3)
- Vomiting Vomiting <=12 hours
- Vomiting Vomiting >12 hours
- Alopecia
- Cardiac dysfunction Asymptomatic
- Cardiac dysfunction Transient
- Cardiac dysfunction Symptomatic
- Nausea
- Mucositis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adriacin CI brief — competitive landscape report
- adriacin updates RSS · CI watch RSS
- Chipscreen Biosciences, Ltd. portfolio CI
Frequently asked questions about adriacin
What is adriacin?
adriacin is a Small molecule drug developed by Chipscreen Biosciences, Ltd., indicated for Acute lymphoid leukemia, Acute myeloid leukemia, disease, Advanced ovarian cancer.
What is adriacin used for?
adriacin is indicated for Acute lymphoid leukemia, Acute myeloid leukemia, disease, Advanced ovarian cancer, Burkitt's lymphoma, Carcinoma of breast.
Who makes adriacin?
adriacin is developed by Chipscreen Biosciences, Ltd. (see full Chipscreen Biosciences, Ltd. pipeline at /company/chipscreen-biosciences-ltd).
Is adriacin also known as anything else?
adriacin is also known as ADR.
What development phase is adriacin in?
adriacin is in Phase 1.
What are the side effects of adriacin?
Common side effects of adriacin include Leukopenia Grade (1,000 to 1,999/mm3), Leukopenia Grade (<1,000/mm3), Thrombocytopenia Grade (25,000 to 49,999/mm3), Thrombocytopenia Grade (<25,000/mm3), Vomiting Vomiting <=12 hours, Vomiting Vomiting >12 hours.
What does adriacin target?
adriacin targets Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase.
Related
- Target: All drugs targeting Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
- Manufacturer: Chipscreen Biosciences, Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute lymphoid leukemia
- Indication: Drugs for Acute myeloid leukemia, disease
- Indication: Drugs for Advanced ovarian cancer
- Also known as: ADR
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing